{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06438757",
      "orgStudyIdInfo": {
        "id": "JYB1904-201"
      },
      "organization": {
        "fullName": "Jemincare",
        "class": "INDUSTRY"
      },
      "briefTitle": "Trial of JYB1904 in Patients With Allergic Asthma",
      "officialTitle": "Phase IIa Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety of JYB1904 in Patients With Allergic Asthma"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-05",
      "overallStatus": "ACTIVE_NOT_RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2024-06-19",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2025-10-31",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2025-10-31",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2024-05-27",
      "studyFirstSubmitQcDate": "2024-05-27",
      "studyFirstPostDateStruct": {
        "date": "2024-06-03",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-05-05",
      "lastUpdatePostDateStruct": {
        "date": "2025-05-07",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Jemincare",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma."
    },
    "conditionsModule": {
      "conditions": [
        "Allergic Asthma"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 69,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "JYB1904: Dose-1",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: JYB1904"
          ]
        },
        {
          "label": "JYB1904: Dose-2",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: JYB1904"
          ]
        },
        {
          "label": "JYB1904: Dose-3",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: JYB1904"
          ]
        },
        {
          "label": "Omalizumab",
          "type": "ACTIVE_COMPARATOR",
          "interventionNames": [
            "Drug: Omalizumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "JYB1904",
          "description": "Participants will receive JYB1904 every 8 weeks for 24 weeks.",
          "armGroupLabels": [
            "JYB1904: Dose-1",
            "JYB1904: Dose-2",
            "JYB1904: Dose-3"
          ]
        },
        {
          "type": "DRUG",
          "name": "Omalizumab",
          "description": "Participants will receive Omalizumab every 2/4 weeks for 24 weeks.",
          "armGroupLabels": [
            "Omalizumab"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Serum concentrations of JYB1904",
          "description": "Serum concentrations of JYB1904, assessed by pre-specified methods",
          "timeFrame": "Baseline through 337 days post-dose"
        },
        {
          "measure": "Serum concentrations of IgE",
          "description": "Serum concentrations of IgE, assessed by pre-specified methods",
          "timeFrame": "Baseline through 337 days post-dose"
        },
        {
          "measure": "Adverse Events(AEs)",
          "description": "Incidence and features of AEs assessed by CTCAE v5.0, and related safety parameters analysis",
          "timeFrame": "Baseline through 337 days post-dose"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Times of protocol-defined asthma exacerbations during the 24-week treatment period",
          "description": "Times of protocol-defined asthma exacerbations during the 24-week treatment period",
          "timeFrame": "Baseline through 168 days post-dose"
        },
        {
          "measure": "Change in spirometry measures of forced expiratory volume in one second (FEV1) in 24 weeks",
          "description": "forced expiratory volume in one second (FEV1)",
          "timeFrame": "Baseline through 24 weeks post-dose"
        },
        {
          "measure": "Serum concentrations of anti-drug antibody (ADA)",
          "description": "Serum ADA assessed by pre-specified methods, and related immunogenic features analysis",
          "timeFrame": "Baseline through 337 days post-dose"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Able to provide written informed consent voluntarily;\n* Aged 18-75 years, weight ≥ 40 kg, male or female;\n* Diagnosed Allergic asthma.\n\nExclusion Criteria:\n\n* Prior exposure to anti-IgE therapy within 1 year;\n* Allergic to anti-IgE biologics;\n* Current smokers, or quit smoking within 1 year;\n* Combined with other non-allergic diseases that cause IgE elevation；\n* History of malignancy, autoimmune diseases, Immune complex mediated diseases, Hypereosinophilic syndrome;\n* Other conditions unsuitable for the trial judged by the investigator.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "75 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Min Zhang",
          "affiliation": "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",
          "role": "STUDY_CHAIR"
        }
      ],
      "locations": [
        {
          "facility": "Shanghai General Hospital",
          "city": "Shanghai",
          "state": "Shanghai Municipality",
          "zip": "201203",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000069444",
          "term": "Omalizumab"
        }
      ],
      "ancestors": [
        {
          "id": "D000888",
          "term": "Antibodies, Anti-Idiotypic"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": false
}